Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

In a major win for Sarepta Therapeutics Inc., US regulators are recommending that patients who can walk be allowed to take ...

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...

Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug ...

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

We recently published 11 Stocks That Jim Cramer Recently Talked About. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT).

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) nosedived by 21.45 percent on Wednesday to end at $36.72 apiece after reporting a disappointing earnings performance in the first quarter of the year.

While Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is already up by more than 30% for the year, analysts on Wall Street remain optimistic about its long-term prospects, with an average price target of ...

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT Provided by PR Newswire Jul 22, 2025 ...

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT Provided by GlobeNewswire Jul 22, 2025, 12:28:00 PM ...